Proteasome inhibition is an attractive approach for anticancer therapy. Doxorubicin (DOX) is
widely used for treatment in a number of cancers including breast cancer; however, the …

Doxorubicin (Dox), one of the most effective chemotherapy drug for cancer treatment, is
limited by its severe side effects and chemoresistance. Dox induces DNA damage and leads …

Background Delanzomib, a novel proteasome inhibitor, has demonstrated promising
efficacy and antitumor ability in human multiple myeloma cell lines and patient‐derived cells …

Doxorubicin (DOX) is the most common chemotherapeutic drug for treatment of breast
cancer but intrinsic and acquired resistance frequently occurs and severe side effects occur …

Background Resistance to chemotherapy is a major problem in the treatment of patients with
triple-negative breast cancer (TNBC). Preclinical data suggest that TNBC is dependent on …

Clinical trials with proteasome inhibitor Bortezomib (also named Velcade or PS-341) has
shown promising results for some cancers. However, other types of cancers including breast …

Triple-Negative Breast Cancer (TNBC) has a poor prognosis due to lack of targeted therapy.
Doxorubicin (DOX) has failed for multiple reasons, including development of multi-drug …

Although effective for the treatment of hematological malignancies, the FDA approved
proteasome inhibitors bortezomib and carfilzomib have limited efficacy in solid tumors …

Background The resistance of cancerous cells to chemotherapy remains the main limitation
for cancer treatment at present. Doxorubicin (DOX) is a potent antitumor drug that activates …

The cellular and molecular effects of the proteasome inhibitor bortezomib on breast cancer
cells are as yet poorly characterized. Here, in a panel of six breast cancer cell lines …